FDA Planning Guidance On Analysis Datasets For Electronic Data Submissions
This article was originally published in The Pink Sheet Daily
Executive Summary
Datasets are needed to support analysis, programs or scripts used in an electronic regulatory submission, CDER Division of Biometrics II Deputy Director Wilson tells DIA symposium on clinical data management. Agency may eventually require analysis datasets to supplement standardized electronic clinical data submissions.
You may also be interested in...
Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses
Agency requested new summary analyses "to better support the new electronic data submission guidelines," the company says.
Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses
Agency requested new summary analyses "to better support the new electronic data submission guidelines," the company says.
Electronic CTD Guidance Forces Applicants To Be More Scientific, CDER Says
CDER’s guidance for electronic common technical documents eliminates the need for paper submissions for virtually every type of drug application. The eCTD forces companies to be more scientific and analyze what they are submitting to FDA, CDER’s Wilson says.